Announcement

FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults (05-24-2018)
Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra... Continue Reading

FDA Approves Aliqopa for Relapsed Follicular Lymphoma (05-23-2018)
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment... Continue Reading

FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (05-21-2018)
On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients... Continue Reading

Anne Arundel Medical Center

Please click here to visit the DeCesaris Cancer Institute website

The DeCesaris Cancer Institute and AAMC Oncology and Hematology are now QOPI (Quality Oncology Practice Initiative) Certified. This demonstrates a commitment to excellence and ongoing quality improvement.
The goals of the QOPI Certification Program are:

1. Promote the highest quality cancer care as defined by the clinician experts.
2. Provide a trusted solution to satisfy external demand for quality activities.
3. Reduce redundant programs or requirements for oncology practices, including health plan programs.